Politics FDA warns of vision loss risk linked to GLP-1 drugs Wegovy, Zepbound Finance News Nov 10, 2026 The U.S. Food and Drug Administration is requiring new safety warnings on all GLP-1 drugs after finding evidence of a… Read More...
Business Pfizer (PFE) earnings Q3 2026 Finance News Nov 3, 2026 Pfizer on Tuesday reported fiscal third-quarter results that topped estimates and hiked its full-year outlook, as… Read More...
Business Merck (MRK) earnings Q3 2026 Finance News Nov 1, 2026 Merck on Thursday topped third-quarter estimates and hiked its adjusted profit outlook, as its immunotherapy… Read More...
Politics Eli Lilly (LLY) earnings Q3 2026 Finance News Oct 29, 2026 Eli Lilly on Thursday reported third-quarter earnings and revenue that blew past estimates and hiked its full-year… Read More...
Earnings J&J falls 6% on an imperfect quarter. Why this is a good chance to buy Finance News Oct 20, 2026 Shares of Johnson & Johnson slid Tuesday after the pharma giant reported another solid but imperfect quarter. But… Read More...
Politics Lilly, Novo bet on amylin obesity drugs after GLP-1s Finance News Oct 2, 2026 The next generation of blockbuster obesity drugs isn't trying to replace GLP-1 medicines.Instead, drugmakers are… Read More...
Business Eli Lilly obesity drug with amylin, tirzepatide boosts weight loss in trial Finance News Sep 30, 2026 Eli Lilly on Wednesday said its experimental combination regimen resulted in greater weight loss than a high dose of… Read More...
Business Novo obesity strategy as Eli Lilly extends lead Finance News Sep 27, 2026 The Eli Lilly and Novo Nordisk logos.Mike Blake | Tom Little | ReutersEvery time Novo urges investors to look ahead,… Read More...
Politics Novo Nordisk CEO on rebuilding investor trust after backlash Finance News Sep 25, 2026 Novo Nordisk CEO Maziar Mike Doustdar waits for the start of the pharmaceutical company’s annual general meeting in… Read More...
Politics Novo CEO signals M&A opportunities to strengthen drug pipeline Finance News Sep 22, 2026 Novo CEO Mike Doustdar told CNBC that the pharmaceutical giant is considering M&A opportunities as it faces… Read More...